Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Neurimmune","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Neurimmune"},{"company":"GliaPharm","sponsor":"Wyss Center","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"GliaPharm"}]

GliaPharm

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

GliaPharm SA and the Wyss Center Enter Collaboration to Develop New Therapies for Alzheimer’s Disease

Details:

The company is currently tackling hypometabolism in an ‘orphan’ neurological disease named Glucose Transporter 1-Deficiency Syndrome. This rare disease is characterized by a reduced entry of glucose into the brain that leads to severe symptoms in children and adults.

Lead Product(s): Undisclosed

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Undisclosed

Partner/Sponsor/Collaborator: Wyss Center

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 24, 2022

ASK
US

Upload
your Pipeline Activity

Neurimmune

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases

Details:

In the new collaboration, companies aim to generate and validate human-derived monoclonal antibodies (NI504) against Ono’s selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resulting from collaboration.

Lead Product(s): Human-derived Monoclonal Antibodies

Therapeutic Area: Neurology Product Name: NI504

Highest Development Status: Discovery Platform Product Type: Large molecule

Partner/Sponsor/Collaborator: Ono Pharmaceutical

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration January 17, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY